Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.31 -1.5%	$1.31	$1.05 ▼ $10.16	$41.70M	1.55	257,470 shs	438,549 shs
ATHE Alterity Therapeutics	$3.92 +2.1%	$4.15	$1.00 ▼ $5.87	$34.09M	0.8	144,307 shs	90,255 shs
DWTX Dogwood Therapeutics	$4.77 -0.6%	$5.11	$1.62 ▼ $29.28	$9.17M	1.88	1.55 million shs	16,329 shs
VOR Vor Biopharma	$0.89 +60.5%	$0.35	$0.13 ▼ $1.80	$111.21M	-0.51	3.43 million shs	281.78 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	-1.50%	+5.65%	+19.09%	-41.52%	-77.41%
ATHE Alterity Therapeutics	+2.08%	-9.68%	-8.41%	+13.95%	+120.04%
DWTX Dogwood Therapeutics	-0.63%	-0.63%	-16.32%	-15.43%	+476,999,900.00%
VOR Vor Biopharma	+60.53%	+315.89%	+412.97%	+18.21%	-22.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRV Acrivon Therapeutics	3.2349 of 5 stars	3.5	5.0	0.6	3.3	0.6
ATHE Alterity Therapeutics	1.4871 of 5 stars	3.3	3.0	0.0	1.7	0.0
DWTX Dogwood Therapeutics	2.1452 of 5 stars	3.5	0.0	3.3	0.0	0.6
VOR Vor Biopharma	2.5574 of 5 stars	4.2	2.0	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	3.00	Buy	$17.71	1,252.24% Upside
ATHE Alterity Therapeutics	2.50	Moderate Buy	$12.00	206.12% Upside
DWTX Dogwood Therapeutics	3.00	Buy	$10.00	109.64% Upside
VOR Vor Biopharma	2.50	Moderate Buy	$7.06	692.94% Upside

Current Analyst Ratings Breakdown

Latest DWTX, ATHE, ACRV, and VOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Outperform
5/16/2025	ACRV Acrivon Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/15/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/9/2025	VOR Vor Biopharma	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	VOR Vor Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform	$6.00 ➝ $6.00
5/9/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
5/8/2025	VOR Vor Biopharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/8/2025	VOR Vor Biopharma	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/8/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Neutral	$7.00 ➝ $0.40
5/5/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
5/4/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$5.68 per share	N/A
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.04 per share	N/A
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	($7.56) per share	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$80.56M	-$2.22	N/A	N/A	N/A	N/A	-44.66%	-40.94%	8/12/2025 (Estimated)
ATHE Alterity Therapeutics	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/4/2025 (Estimated)
DWTX Dogwood Therapeutics	-$12.35M	-$18.04	N/A	N/A	N/A	N/A	-217.12%	-34.74%	8/6/2025 (Estimated)
VOR Vor Biopharma	N/A	-$1.51	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest DWTX, ATHE, ACRV, and VOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ACRV Acrivon Therapeutics	-$0.57	-$0.51	+$0.06	-$0.51	N/A	N/A
5/8/2025	Q1 2025	DWTX Dogwood Therapeutics	-$0.77	-$4.21	-$3.44	-$8.45	N/A	N/A
3/31/2025	Q4 2024	DWTX Dogwood Therapeutics	-$1.49	-$6.29	-$4.80	-$6.29	N/A	N/A
3/27/2025	Q4 2024	ACRV Acrivon Therapeutics	-$0.69	-$0.60	+$0.09	-$0.60	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	11.17	11.17
ATHE Alterity Therapeutics	N/A	3.84	N/A
DWTX Dogwood Therapeutics	N/A	7.43	7.43
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
ATHE Alterity Therapeutics	2.14%
DWTX Dogwood Therapeutics	9.05%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	11.90%
ATHE Alterity Therapeutics	38.80%
DWTX Dogwood Therapeutics	3.90%
VOR Vor Biopharma	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	31.35 million	27.62 million	Not Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.43 million	Not Optionable
DWTX Dogwood Therapeutics	5	1.91 million	1.84 million	N/A
VOR Vor Biopharma	140	124.96 million	65.45 million	Not Optionable

DWTX, ATHE, ACRV, and VOR Headlines

Recent News About These Companies

Vor, with new CEO, changes course to target autoimmune disease

June 26 at 8:41 PM | biopharmadive.comB

After axing 95% workforce, Vor bets $4B+ on Remegen’s telitacicept

June 26 at 8:41 PM | bioworld.comB

Vor Biopharma Insider Trading Activity | NASDAQ:VOR | Benzinga

June 26 at 3:39 PM | benzinga.com

Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions

June 26 at 3:39 PM | fiercepharma.comF

Vor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune Therapy

June 26 at 3:39 PM | msn.com

Vor Biopharma Target of Unusually High Options Trading (NYSE:VOR)

June 26 at 11:31 AM | marketbeat.com

Vor Biopharma: Vor Bio Announces $175 Million Private Placement

June 26 at 10:37 AM | finanznachrichten.de

Vor Biopharma: Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

June 26 at 10:37 AM | finanznachrichten.de

Vor Biopharma stock soars after licensing deal for autoimmune therapy

June 26 at 10:37 AM | investing.com

Wedbush Reaffirms "Neutral" Rating for Vor Biopharma (NYSE:VOR)

June 26 at 10:00 AM | marketbeat.com

Vor Bio Announces $175 Million Private Placement

June 25 at 5:03 PM | globenewswire.com

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

June 25 at 4:45 PM | globenewswire.com

Estimating The Fair Value Of Vor Biopharma Inc. (NASDAQ:VOR)

June 25 at 1:59 PM | finance.yahoo.com

Vor Biopharma Stock Price History - Investing.com

June 24 at 10:56 PM | investing.com

Vor Biopharma Inc. (VOR) Latest Stock News & Headlines - Yahoo Finance

June 24 at 10:56 PM | finance.yahoo.com

Vor Bio details extent of Cambridge layoffs in state filing

June 2, 2025 | bizjournals.com

Cambridge biotech company researching blood cancers to close, lay off 155

June 2, 2025 | masslive.comM

Vor Biopharma Inc. Advanced Charts - Barron's

May 29, 2025 | barrons.com

RA Capital's biotech incubator lays off staffers: Stat

May 15, 2025 | fiercebiotech.comF

Stifel cuts Vor Biopharma stock rating amid clinical and financial concerns

May 10, 2025 | investing.com

JMP Securities Downgrades Vor Biopharma (VOR)

May 9, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX, ATHE, ACRV, and VOR Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.31 -0.02 (-1.50%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.31 0.00 (0.00%)

As of 04:03 AM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Alterity Therapeutics NASDAQ:ATHE

$3.92 +0.08 (+2.08%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$4.10 +0.18 (+4.57%)

As of 06/26/2025 06:05 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Dogwood Therapeutics NASDAQ:DWTX

$4.77 -0.03 (-0.63%)

Closing price 06/26/2025 03:59 PM Eastern

Extended Trading

$4.75 -0.02 (-0.42%)

As of 04:17 AM Eastern

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Vor Biopharma NYSE:VOR

$0.89 +0.34 (+60.53%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$0.95 +0.06 (+7.19%)

As of 04:44 AM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time